EBS
Price
$11.72
Change
+$0.16 (+1.38%)
Updated
Dec 11 closing price
Capitalization
615.53M
88 days until earnings call
Intraday BUY SELL Signals
HKMPF
Price
$20.48
Change
-$0.34 (-1.63%)
Updated
Dec 11 closing price
Capitalization
4.54B
Intraday BUY SELL Signals
Interact to see
Advertisement

EBS vs HKMPF

Header iconEBS vs HKMPF Comparison
Open Charts EBS vs HKMPFBanner chart's image
Emergent Biosolutions
Price$11.72
Change+$0.16 (+1.38%)
Volume$651.32K
Capitalization615.53M
Hikma Pharmaceuticals
Price$20.48
Change-$0.34 (-1.63%)
Volume$500
Capitalization4.54B
EBS vs HKMPF Comparison Chart in %
EBS
Daily Signal:
Gain/Loss:
HKMPF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EBS vs. HKMPF commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Buy and HKMPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (EBS: $11.72 vs. HKMPF: $20.48)
Brand notoriety: EBS and HKMPF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EBS: 58% vs. HKMPF: 39%
Market capitalization -- EBS: $615.53M vs. HKMPF: $4.54B
EBS [@Pharmaceuticals: Generic] is valued at $615.53M. HKMPF’s [@Pharmaceuticals: Generic] market capitalization is $4.54B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 2 FA rating(s) are green whileHKMPF’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 2 green, 3 red.
  • HKMPF’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than HKMPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 5 TA indicator(s) are bullish while HKMPF’s TA Score has 3 bullish TA indicator(s).

  • EBS’s TA Score: 5 bullish, 3 bearish.
  • HKMPF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EBS is a better buy in the short-term than HKMPF.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а -2.74% price change this week, while HKMPF (@Pharmaceuticals: Generic) price change was -4.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.50%. For the same industry, the average monthly price growth was -1.01%, and the average quarterly price growth was +19.25%.

Reported Earning Dates

EBS is expected to report earnings on Mar 10, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.50% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HKMPF($4.54B) has a higher market cap than EBS($616M). HKMPF has higher P/E ratio than EBS: HKMPF (12.26) vs EBS (8.88). EBS YTD gains are higher at: 22.594 vs. HKMPF (-12.187). HKMPF has higher annual earnings (EBITDA): 734M vs. EBS (344M). EBS has more cash in the bank: 267M vs. HKMPF (236M). EBS has less debt than HKMPF: EBS (668M) vs HKMPF (1.56B). HKMPF has higher revenues than EBS: HKMPF (3.22B) vs EBS (812M).
EBSHKMPFEBS / HKMPF
Capitalization616M4.54B14%
EBITDA344M734M47%
Gain YTD22.594-12.187-185%
P/E Ratio8.8812.2672%
Revenue812M3.22B25%
Total Cash267M236M113%
Total Debt668M1.56B43%
FUNDAMENTALS RATINGS
EBS vs HKMPF: Fundamental Ratings
EBS
HKMPF
OUTLOOK RATING
1..100
1033
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3278
PRICE GROWTH RATING
1..100
3862
P/E GROWTH RATING
1..100
696
SEASONALITY SCORE
1..100
3850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HKMPF's Valuation (5) in the null industry is somewhat better than the same rating for EBS (59) in the Biotechnology industry. This means that HKMPF’s stock grew somewhat faster than EBS’s over the last 12 months.

HKMPF's Profit vs Risk Rating (100) in the null industry is in the same range as EBS (100) in the Biotechnology industry. This means that HKMPF’s stock grew similarly to EBS’s over the last 12 months.

EBS's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for HKMPF (78) in the null industry. This means that EBS’s stock grew somewhat faster than HKMPF’s over the last 12 months.

EBS's Price Growth Rating (38) in the Biotechnology industry is in the same range as HKMPF (62) in the null industry. This means that EBS’s stock grew similarly to HKMPF’s over the last 12 months.

EBS's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for HKMPF (96) in the null industry. This means that EBS’s stock grew significantly faster than HKMPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSHKMPF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
35%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 2 days ago
44%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 2 days ago
34%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 2 days ago
35%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 2 days ago
34%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 2 days ago
43%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 2 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signal:
Gain/Loss:
HKMPF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMIDX18.920.19
+1.01%
Congress Mid Cap Growth Retail
ETMGX30.710.26
+0.85%
Eaton Vance Tx-Mgd Small-Cap A
PINRX17.050.05
+0.29%
Principal Diversified Intl R3
CAFAX47.780.11
+0.23%
American Funds AMCAP 529A
PHEIX13.12-0.74
-5.34%
T. Rowe Price Hedged Equity I

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+1.38%
SIGA - EBS
40%
Loosely correlated
+4.32%
VTRS - EBS
35%
Loosely correlated
-0.09%
ELAN - EBS
34%
Loosely correlated
-0.14%
CRON - EBS
33%
Poorly correlated
+2.15%
CGC - EBS
31%
Poorly correlated
-1.74%
More

HKMPF and

Correlation & Price change

A.I.dvisor tells us that HKMPF and AMPH have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HKMPF and AMPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HKMPF
1D Price
Change %
HKMPF100%
-1.63%
AMPH - HKMPF
24%
Poorly correlated
+0.74%
CAIHF - HKMPF
24%
Poorly correlated
N/A
HLTRF - HKMPF
11%
Poorly correlated
N/A
GRUSF - HKMPF
9%
Poorly correlated
-0.09%
ESALF - HKMPF
7%
Poorly correlated
N/A
More